SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Bliss GVS Pharma Unit Gets MHRA Authorization for Mesalazine Suppositories

The authorization is a specific regulatory milestone for the company’s mesalazine product.

BLISSGVS

Related stories